Sentences with phrase «growth in the share price»

In large part this has been driven by growth in share prices and house prices, although the demutualisation of the AMP Society and capital gains from the first stage of the Telstra float provided an additional boost to available wealth last year.

The cash benefits are linked to the growth in the share price

But investors shouldn't expect as much growth in the share price as there might be with a growth stock.

Still, plans to step up production of its electric cars continue to drive interest and growth in its share price.

Not exact matches

Huber of T. Rowe Price foresees high - single - digit earnings - per - share growth, and 15 % share - price upside in the next couple of years, even before factoring in yPrice foresees high - single - digit earnings - per - share growth, and 15 % share - price upside in the next couple of years, even before factoring in yprice upside in the next couple of years, even before factoring in yield.

Solid growth in the late»90s gave way to a tumbling share price in 2000.

Certainly no one is predicting large declines in profits or share prices, but rather a period of much more modest growth.

When you purchase a broad swath of equities, say an S&P 500 index fund, the returns you can expect over the next decade or so comprise four building blocks: the starting dividend yield, projected growth in real earnings per share, expected inflation, and the expected change in «valuation» — that is, the expansion or contraction in the price / earnings (P / E) multiple.

Critics say the firm isn't focused enough on organic growth, and since those giddy chart - topping days in late July, the share price has declined: Valeant no longer holds its No.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

Dip in share prices and bond yields, along with the upcoming election has had an impact on the state of the global economy, causing a setback in business travel growth.

But don't confuse that spike in the share price with a surge in optimism about Apple's future growth.

But growth is the main driver for M&A deals: Not just growth in drug distribution scale or earnings growth through cost - cutting, but in revenues — and especially share price.

During his tenure with AlliedSignal, the company achieved consistent growth in earnings and cash flow, highlighted by 31 consecutive quarters of earnings - per - share growth of 13 % or more and an eight-fold appreciation of the company's share price.

The company's financial performance in the year to date has been mixed after its decision to raise the prices of its products weakened its market share and forced it to trim its sales growth forecast for the full year.

The uncertainty around the globe — including decrease in share prices and bond yields, along with the upcoming election — has had an impact on growth in the business travel industry.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

We believe share price growth of 20 percent to 30 percent is very much in the cards here.

The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and notable return on equity.

The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, notable return on equity and solid stock price performance.

At its current valuation of ~ $ 67 / share, HLF has a price to economic book value ratio (price - to - EBV) of 1.2 That ratio means that the market expects only 20 % growth in NOPAT for the remainder of HLF's existence.

The immediate question raised by a fall in share prices of that sort of order is the size of its impact on global growth.

These included overly optimistic economic growth and oil price assumptions; cutting the contingency reserve by two - thirds; selling shares in GM at fire sale prices; raiding EI revenues; and even booking «savings» from unilateral changes to federal employees» sick leave benefits.

Indeed, the strong growth of investor housing loans has driven the growth in household debt (as a share of disposable incomes) over recent years and contributed to a rise in both housing prices and dwelling construction.

Under the Bonus Plan, our compensation committee, in its sole discretion, determines the performance goals applicable to awards, which goals may include, without limitation: attainment of research and development milestones, sales bookings, business divestitures and acquisitions, cash flow, cash position, earnings (which may include any calculation of earnings, including but not limited to earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation and amortization and net earnings), earnings per share, net income, net profit, net sales, operating cash flow, operating expenses, operating income, operating margin, overhead or other expense reduction, product defect measures, product release timelines, productivity, profit, return on assets, return on capital, return on equity, return on investment, return on sales, revenue, revenue growth, sales results, sales growth, stock price, time to market, total stockholder return, working capital, and individual objectives such as MBOs, peer reviews, or other subjective or objective criteria.

Our fundamental belief is that growth in corporate profits and the resultant dividend growth will eventually lead to share price appreciation.

This has been underpinned by strong growth in profits so that, notwithstanding the rise in share prices, P / E ratios have been declining on average.

The economic effects can be seen in a number of areas including strong growth in business investment, company profits, share prices and imports.

While the liberalizing reforms usually undermine the ability of the elite to capture a disproportionate share of growth, in other words, because the reforms often seem to encourage massive foreign capital inflows, and these push up the price of assets largely controlled by the elite, political opposition to the reforms is weakened.

Figure 1 shows this value - destroying behavior in action for GE (GE) by comparing between the amount of money spent buying back shares and the price to economic book value (PEBV), a measure of the growth expectations embedded in the stock price.

While the $ 2.36 per share offer only implies a «small» 15 per cent takeover premium to Deutsche's $ 2.05 price target, the research team points to «recent operational risks in the hospital portfolio, the execution risks of the Northern Beaches greenfield project and our lower revenue growth outlook for the private hospital industry.»

Important factors that may affect the Company's business and operations and that may cause actual results to differ materially from those in the forward - looking statements include, but are not limited to, increased competition; the Company's ability to maintain, extend and expand its reputation and brand image; the Company's ability to differentiate its products from other brands; the consolidation of retail customers; the Company's ability to predict, identify and interpret changes in consumer preferences and demand; the Company's ability to drive revenue growth in its key product categories, increase its market share, or add products; an impairment of the carrying value of goodwill or other indefinite - lived intangible assets; volatility in commodity, energy and other input costs; changes in the Company's management team or other key personnel; the Company's inability to realize the anticipated benefits from the Company's cost savings initiatives; changes in relationships with significant customers and suppliers; execution of the Company's international expansion strategy; changes in laws and regulations; legal claims or other regulatory enforcement actions; product recalls or product liability claims; unanticipated business disruptions; failure to successfully integrate the Company; the Company's ability to complete or realize the benefits from potential and completed acquisitions, alliances, divestitures or joint ventures; economic and political conditions in the nations in which the Company operates; the volatility of capital markets; increased pension, labor and people - related expenses; volatility in the market value of all or a portion of the derivatives that the Company uses; exchange rate fluctuations; disruptions in information technology networks and systems; the Company's inability to protect intellectual property rights; impacts of natural events in the locations in which the Company or its customers, suppliers or regulators operate; the Company's indebtedness and ability to pay such indebtedness; the Company's dividend payments on its Series A Preferred Stock; tax law changes or interpretations; pricing actions; and other factors.

But if you are a high - flying growth company that is expected to grow earnings per share at 20 % every year, and you know that your stock price will plummet the first moment you post disappointing results, the incentive to engage in fraudulent behavior seems a lot greater.

In 2015, news reports revealed that Uber had an operating loss of $ 470 million on $ 415 million in revenue, confirming suspicions that the company has been bleeding money for the sake of achieving steep growth and acquiring market share.391 In China, the company has lost more than $ 1 billion a year.392 The strategy of aggressive price competition and brazen leadership coupled with soaring growth prompted immediate comparisons to Amazon.393 Like Amazon, Uber has drawn immense interest from investorIn 2015, news reports revealed that Uber had an operating loss of $ 470 million on $ 415 million in revenue, confirming suspicions that the company has been bleeding money for the sake of achieving steep growth and acquiring market share.391 In China, the company has lost more than $ 1 billion a year.392 The strategy of aggressive price competition and brazen leadership coupled with soaring growth prompted immediate comparisons to Amazon.393 Like Amazon, Uber has drawn immense interest from investorin revenue, confirming suspicions that the company has been bleeding money for the sake of achieving steep growth and acquiring market share.391 In China, the company has lost more than $ 1 billion a year.392 The strategy of aggressive price competition and brazen leadership coupled with soaring growth prompted immediate comparisons to Amazon.393 Like Amazon, Uber has drawn immense interest from investorIn China, the company has lost more than $ 1 billion a year.392 The strategy of aggressive price competition and brazen leadership coupled with soaring growth prompted immediate comparisons to Amazon.393 Like Amazon, Uber has drawn immense interest from investors.

Taking account of all this, share prices seem to assume there will be an implausible rate of growth in profits.

Much of the record growth in corporate EPS has been driven by lower interest expense, lower commodity prices and share buybacks as top line growth has been sub-par.

Shares of Dunkin' slid 12 % on Thursday as it reported slowing sales growth in the third quarter, when menu prices were raised by franchisees following a contentious summer of minimum wage discussions in the country.

Mac — in a declining PC industry, we expect Mac to continue its market share gain and support our forecast for its strong performance of 7.3 % revenue growth in FY 2015, followed by 3.6 % in FY 2016, and 4.6 % in FY 2017 on flat average selling prices over the three year period of $ 1,230.

If the fundamentals are solid and the company is enhancing shareholder value by generating consistent bottom - line growth, the share price should reflect that in the long - term.

For example, an investor that ponders the probability that a company will report a certain earnings growth rate over a five - or ten - year period is much more apt to ride out short - term fluctuations in the share price.

Meanwhile, investors will anticipate faster future growth in output and profits, pushing up share prices.

Bought in 2012 at $ 37 / share and annual dividend of $ 1.44 2015 share price of $ 79 / share and annual dividend of $ 1.84 Share price capital gain = 113 %, Total dividend growth = 27.7 % Prune Ratio: 113 / 27.7 =share and annual dividend of $ 1.44 2015 share price of $ 79 / share and annual dividend of $ 1.84 Share price capital gain = 113 %, Total dividend growth = 27.7 % Prune Ratio: 113 / 27.7 =share price of $ 79 / share and annual dividend of $ 1.84 Share price capital gain = 113 %, Total dividend growth = 27.7 % Prune Ratio: 113 / 27.7 =share and annual dividend of $ 1.84 Share price capital gain = 113 %, Total dividend growth = 27.7 % Prune Ratio: 113 / 27.7 =Share price capital gain = 113 %, Total dividend growth = 27.7 % Prune Ratio: 113 / 27.7 = 4.03

«Boards that authorise share - repurchase initiatives at market prices below what the businesses are intrinsically worth per share (without foregoing investment in even more compelling growth opportunities and with due regard for the financial security of the remaining shareholders) are clearly putting the shareholder's interest high on the priority list» Frank Martin

While these network effects have generated enormous revenues, today's glamour stocks also trade at earnings and price / revenue multiples that have historically been reserved for companies at a much earlier point in their growth trajectories, not for mature companies with already overwhelming market share.

Bought in 2013 at $ 77 / share and annual dividend of $ 2.40 2015 share price of $ 80 / share and annual dividend of $ 2.65 Share price total return = 3 %, Total Dividend Growth = 10.4 % Prune Ratio: 3 / 10.4 =share and annual dividend of $ 2.40 2015 share price of $ 80 / share and annual dividend of $ 2.65 Share price total return = 3 %, Total Dividend Growth = 10.4 % Prune Ratio: 3 / 10.4 =share price of $ 80 / share and annual dividend of $ 2.65 Share price total return = 3 %, Total Dividend Growth = 10.4 % Prune Ratio: 3 / 10.4 =share and annual dividend of $ 2.65 Share price total return = 3 %, Total Dividend Growth = 10.4 % Prune Ratio: 3 / 10.4 =Share price total return = 3 %, Total Dividend Growth = 10.4 % Prune Ratio: 3 / 10.4 = 0.28

If you solve for»n' such that the present value of the cash flows is equal to the share price you get an indication of the growth rate implied in the stock price.

- What are the implied growth rates in the current share price?

Bought in 2011 at $ 12.22 / share and annual dividend of $ 0.63 2015 share price at $ 16.44 / share and annual dividend of $ 0.67 Share price capital gain = 32 %, Total dividend growth = 6.9 % Prune Ratio: 32 / 6.9 =share and annual dividend of $ 0.63 2015 share price at $ 16.44 / share and annual dividend of $ 0.67 Share price capital gain = 32 %, Total dividend growth = 6.9 % Prune Ratio: 32 / 6.9 =share price at $ 16.44 / share and annual dividend of $ 0.67 Share price capital gain = 32 %, Total dividend growth = 6.9 % Prune Ratio: 32 / 6.9 =share and annual dividend of $ 0.67 Share price capital gain = 32 %, Total dividend growth = 6.9 % Prune Ratio: 32 / 6.9 =Share price capital gain = 32 %, Total dividend growth = 6.9 % Prune Ratio: 32 / 6.9 = 4.63

FedEx still offers an earnings growth rate that is high for large companies, yet we were able to purchase shares at prices that were first seen in 2003, even though earnings per share have more than doubled over the period.

Even if bears are right and Verizon is unable to compete in the price wars of the mobile industry, Verizon's current economic book value, or no growth value, is $ 61 / share, which represents 33 % upside from the current price.